Public Health | November 16, 2021
Biocon Biologics partners with RSSDI to expand insulin access
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The centre has an initial capacity of 500 FTEs
The consideration for the acquisition is US $ 2.25 million
LSDCheck is CE-IVD approved LCMSMS-based testing kit for LSD in newborns
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
Subscribe To Our Newsletter & Stay Updated
